Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
News|Articles|April 28, 2026
The Acceleration of Psychedelic-Based Treatments: In Conversation With Daniel R. Karlin, MD, MA
Author(s)Leah Kuntz, Daniel R. Karlin, MD, MA
Read our exclusive interview with Daniel R. Karlin, MD, MA, on the latest executive order, DT120 for the treatment of mental health disorders, and more.
Advertisement
Advertisement
CLINICAL CONVERSATIONS
Related to this article
BCG vaccination curbs tau tangles in mice by boosting microglial cleanup, fueling hopes for human trials to reduce dementia risk.
GLP-1 weight-loss drugs may worsen eating disorders or mask symptoms; experts urge careful screening, specialist referral, and monitoring before, during, and after use.
Psychedelic trials often exclude real-world comorbidities; clinicians must weigh blinding limits, dosing durability, support needs, safety risks, and uneven system readiness.
New automated connectomics maps synapses across circuits, revealing how inhibitory neuron subtypes shape decision-making and may explain circuit dysfunction in psychiatric disorders.
Advertisement
Advertisement